INTRODUCTION
We describe a 7-day-old infant who presented with extensive cerebral venous sinus thrombosis (CVST) and was found to be homozygous for the prothrombin G20210A gene mutation. No other known risk factors for thrombosis were identified.
PATIENT REPORT
A 7-day-old female presented to our hospital with a 1-day history of decreased feeding, decreased activity and shaking of her extremities. She was born at 42 weeks gestation to a 30-year-old primagravida healthy mother via uncomplicated vaginal delivery. In the Emergency Center, the vital signs were temperature 36.21C, heart rate 160 beats per minute, respiratory rate 48 per minute, blood pressure 119/66 mmHg, and oxygen saturation of 95% on room air. Her weight was 3.1 kg that was 4% below birth weight. The head circumference was unchanged from birth at 37 cm. The infant was hypotonic with minimal response to the examination, blood draws, and IV placement. She had subtle seizures associated with apnea. An endotracheal tube was placed and mechanical ventilation initiated. A lumbar puncture was nontraumatic but revealed bloody cerebrospinal fluid (CSF). The CSF red blood cell (RBC) count was 874,800 ml À1 , white blood cell (WBC) count 500 ml
À1
, protein 844 mg/dl, glucose 38 mg/dl, the Gram stain was negative and the PCR for the herpes simplex virus type I and II was negative. Other laboratory values were WBC 16 bil/l, hemoglobin 15.5 g/dl, platelets 116 bil/l, PT 12.6 seconds, PTT 29.9 seconds, Fibrinogen 92 mg/dl, and D-Dimer >0.5 mg/l. Fibrin stabilizing factor was present. Electrolytes, including calcium, magnesium and phosphorus, were normal. Blood, urine and CSF cultures were negative. She received intravenous phenobarbital, ampicillin and gentamicin. A computed tomography (CT) scan of the head revealed an intraventricular and left thalamic hemorrhage with mild hydrocephalus as well as cerebral venous sinus thrombosis involving the right transverse and sigmoid sinuses ( Figure 1) . A magnetic resonance imaging (MRI) with magnetic resonance venography (MRV) and arteriography (MRA) better delineated the extensive cerebral venous sinus thrombosis of the superior sagittal sinus, straight sinus, right transverse, sigmoid sinuses and left internal cerebral vein (Figure 2 ). Heparin anticoagulation was not started because of the large intraventricular and thalamic hemorrhage. Selective catheterization of the clotted cerebral veins was performed to disrupt the clot mechanically and re-establish venous blood flow, and in situ thrombolytics were not given because of the large intracranial hemorrhage. Evaluation for thrombophilia showed homozygous G20210A mutation in the prothrombin gene and heterozygous C677 T mutation in the MTHFR gene. Genotyping for factor V Leiden was normal. Homocysteine level was slightly depressed at 4.7 mmol/l (normal 6 to 16). Protein C activity was 37% (normal 70 to 140), protein C antigen was 41% (70 to 150). Protein S antigen total was 52% (60 to 150) and free 95% (48 to 160). Antithrombin level was 30% (80 to 120). Antiphospholipid antibodies panel was negative. The organic and amino acids screen was normal. There was no family history of thrombophilia. The parents were referred to an adult thrombologist and both were heterozygous for the prothrombin G20210A mutation and the mother has sticky platelet syndrome.
Her neurological examination improved, and after 3 days the endotracheal tube was removed and she began to feed and was stable on room air. At 14 days of age, she had a tonic-clonic seizure, became acutely cyanotic and limp with agonal breathing. The endotracheal tube was placed and lorazepam was given to stop the seizures. Despite mechanical ventilation and circulatory support, she remained hypoxic and poorly perfused. Pulmonary embolism with acute cor pulmonale was suspected because of low end-tidal PCO2 (PETCO2). Intravenous tissue plasminogen activator (tPA) was given with appropriate rise of PETCO2, but she died within a few hours despite vigorous resuscitation. The parents refused autopsy.
DISCUSSION
CVST is a relatively uncommon disorder in children. In a large multicenter Canadian study the incidence was 0.67/100,000 children/year, 43% under 1 month of age. 1 The German Pediatric Thrombophilia Registry reported an incidence of 2.6/100,000 neonates/year and 0.35/100,000 children/year. 2 Seizures are the presenting feature in 71% of neonates with CVST.
1 MRI and MRV are the imaging studies of choice, because brain CT is falsely negative in up to 16% of patients. 1 CVST may cause venous cerebral infarcts and hemorrhage because of occluded venous outflow. In our patient, the thrombosed straight sinus and internal cerebral vein likely caused the thalamic and intraventicular hemorrhages. Prothrombotic risk factors are present in 39 to 54% of children with CVST.
1,2 These include factor V G1691A (Leiden) mutation, prothrombin G20210A mutation, methylenetetrahydrofolate reductase (MTHFR) C677 T mutation, protein C, protein S and antithrombin III deficiency, elevated lipoprotein (a) levels and antiphospholipid antibodies. It is common to identify more than one genetic risk factor and 70% of these children have a contributing clinical condition as well as the genetic prothrombotic risk factors. 2 The prothrombin G20210A mutation is a substitution of guanine (G) by adenine (A) at nucleotide position 20210 of the prothrombin gene on chromosome 11.
3 Carriers (heterozygotes) of the 20210A allele have higher plasma prothrombin levels than individuals with a normal genotype and have a 2.8-fold increased risk of venous thrombosis. 3 The elevated prothrombin level is due to a higher translation efficiency of gene mRNA or higher stability of the transcribed mRNA. 3 The mutation was found in 18% of patients with documented family history of venous thrombosis and in 6.2% of unselected patients with a first episode of deep vein thrombosis compared with 1 to 2% of healthy control subjects. 3 It is the second most common genetic prothrombotic risk factor after factor V Leiden mutation. The homozygous state of the prothrombin G20210A mutation is rare with an estimated prevalence of 0.014% in the general population. 3 This mutation has a predilection for central nervous system thrombosis. 4 Arterial stroke is more common in children less than 2 years of age and CVST in those older than 2 years. 4 Adults have a five-fold increased risk of CVST, but not an increased risk of arterial stroke. 5 The prevalence of the prothrombin G20210A mutation in children with CVST ranges between 4.7 and 10% 2, 4, 6 and is 20% in adults with CSVT. 7 In these reports, all of the children and adults with the prothrombin mutation and CVST were heterozygous. Homozygous prothrombin G20210A mutation was reported in a 3-year old with arterial stroke, 4 a 15-year old with DVT using oral contraceptives, 4 a 13-year old with recurrent pulmonary embolism 8 and in a 19-year old with bilateral iliac vein thrombosis. 9 However, adult homozygotes for prothrombin G20210A may be asymptomatic.
10,11 Methylenetetrahydrofolate reductase (MTHFR) is one of several enzymes involved in homocysteine metabolism. The C6777 T mutation of the MTHFR gene makes the enzyme less active resulting in an elevated homocysteine level and increasing the risk for thrombosis. This mutation is common in the general population and has not been shown to be associated with venous thrombosis. In one study, the heterozygous C6777 T mutation of the MTHFR gene was present in 15.4% of neonates with cerebral thrombosis and in 34.2% of controls. 6 In addition, the homocysteine level was not elevated in our patient and it is unlikely that this mutation played any role in the development of CVST.
Protein C, protein S or antithrombin deficiency are known causes of thrombosis. However, these natural anticoagulants are consumed by fresh blood clots, and it is likely that the depressed levels of protein C, protein S and antithrombin in our patient were related to consumption of these factors by the acute clot rather than a cause of thrombosis. These levels should be obtained when the patient is healthy and not receiving anticoagulation.
It is important to identify the genetic prothrombotic mutations in children with thrombosis and to provide genetic counseling and testing of family members. For example, females in the reproductive age would be counseled against the use of oral contraceptives. Women with prothrombin G20210A mutation who take oral contraceptives have a 14-fold increased risk of CVST compared with women taking oral contraceptives but without the mutation 5 and a 150-fold increased risk compared with women with neither risk factor. 7 The treatment of CVST is controversial especially in children. Observation with supportive treatment, anticoagulation and localized thrombolysis have all been used. There are no randomized controlled trials in children and two in adults. 12, 13 There were no deaths in 10 adults treated with unfractionated heparin compared with 3/10 given placebo. 12 The second trial showed no benefit for patients treated with low-molecular-weight heparin (LMWH). 13 Both unfractionated heparin and LMWH have been shown to be safe in the treatment of a large number of children with CVST, 1, 2 including patients with intracranial bleed, but their efficacy in reducing mortality or long-term sequelae is unproven. We chose not to use anticoagulation in our patient because of the large intracranial hemorrhage.
